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Abstract The aim of the present study is to determine
and compare initial treatment costs of microsurgery, linear
accelerator (LINAC) radiosurgery, and gamma knife radi-
osurgery in meningioma patients. Additionally, the follow-
up costs in the first year after initial treatment were
assessed. Cost analyses were performed at two neurosur-
gical departments in The Netherlands from the healthcare
providers’ perspective. A total of 59 patients were inclu-
ded, of whom 18 underwent microsurgery, 15 underwent
LINAC radiosurgery, and 26 underwent gamma knife
radiosurgery. A standardized microcosting methodology
was employed to ensure that the identified cost differences
would reflect only actual cost differences. Initial treatment
costs, using equipment costs per fraction, were €12,288 for
microsurgery, €1,547 for LINAC radiosurgery, and €2,412
for gamma knife radiosurgery. Higher initial treatment
costs for microsurgery were predominantly due to inpatient
stay (€5,321) and indirect costs (€4,350). LINAC and
gamma knife radiosurgery were equally expensive when
equipment was valued per treatment (€2,198 and €2,412,
respectively). Follow-up costs were slightly, but not sig-
nificantly, higher for microsurgery compared with LINAC
and gamma knife radiosurgery. Even though initial treat-
ment costs were over five times higher for microsurgery
compared with both radiosurgical treatments, our study
gives indications that the relative cost difference may
decrease when follow-up costs occurring during the first
year after initial treatment are incorporated. This reinforces
the need to consider follow-up costs after initial treatment
when examining the relative costs of alternative treatments.
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Introduction
Meningiomas are common tumors of the central nervous
system that originate from the meningeal coverings of the
spinal cord and the brain; they account for up to 30% of all
primary brain tumors [1]. Intracranial meningiomas are
most commonly reported in adults in their fourth through
sixth decades of life and are more common in women, with
a female preponderance of about 2:1 [2]. The incidence
of meningiomas is climbing, which may indicate more
sensitive diagnostic modalities or increased exposure to
environmental risk factors [3]. Meningiomas are generally
slow-growing benign tumors with a broad spectrum of
clinical characteristics. According to the World Health
Organization (WHO) classification, the most commonly
used grading system for meningiomas, there are three
malignancy grades: benign (grade I), atypical (grade II),
and anaplastic or malignant (grade III) [4].
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The gold-standard procedure for treatment of meningi-
oma is microsurgery. Even though advances in microsur-
gical approaches have greatly improved patient outcomes
for meningioma once thought to be unresectable, long-term
cure remains a desirable but elusive goal [5]. Besides,
microsurgery is costly, being a labor-intensive inpatient
procedure [6–8]. Therefore, stereotactic radiosurgery, the
delivery of a high, single dose of radiation to a discrete
tumor volume, is increasingly accepted as an alternative to
conventional microsurgery in selected patients [8, 9].
Radiosurgery, either with linear accelerator (LINAC) or
gamma knife, is able to target surgically inaccessible or
difficult lesions and has decreased risk of complications
related to surgery and anesthesia [5, 7, 10, 11]. Radiosur-
gical patients may experience higher quality of life than
microsurgical patients, especially in the short term, because
radiosurgery is a minimally invasive outpatient procedure
[6, 12, 13]. Advantages of LINAC radiosurgery include
relatively low costs and high accessibility. Gamma knife
radiosurgery has been suggested to be more accurate, but
its costs are higher and accessibility lower than LINAC
radiosurgery, particularly due to its high equipment costs
[10, 14].
To date, few studies have compared treatment costs of
alternative treatments in patients with intracranial tumor,
such as acoustic neuromas and vestibular schwannomas,
and most of them are outdated [15–19]. Of the studies
performed in the past 5 years, three compared microsur-
gery with gamma knife radiosurgery [6, 8, 12]. Another
study made a cost comparison between LINAC and gamma
knife radiosurgery [10]. However, these studies neither
compared the initial treatment costs of microsurgery,
LINAC radiosurgery, and gamma knife radiosurgery nor
compared alternative treatments in meningioma. Therefore,
the aim of the present study is to calculate initial treatment
costs of microsurgery, LINAC radiosurgery, and gamma
knife radiosurgery in meningioma patients from a health-
care providers’ perspective.
The microcosting methodology is generally considered
to be the gold-standard methodology for costing hospital
services, because it identifies all relevant cost components
at the most detailed level [20, 21]. The methodology allows
for identification of costs per patient and for insight into
patient subgroups that might account for a large share of
total costs. Therefore, the microcosting methodology was
used to calculate initial treatment costs in our meningioma
patients.
The healthcare providers’ perspective also includes fol-
low-up costs which occur after initial treatment. Ignoring
these follow-up costs could result in unfair conclusions
regarding the relative costs of alternative treatments [6, 20].
Therefore, this study additionally aims to calculate the
follow-up costs in the first year after initial treatment with
microsurgery, LINAC radiosurgery, and gamma knife
radiosurgery.
Methods
To be able to make a truthful comparison between micro-
surgery, LINAC radiosurgery, and gamma knife radiosur-
gery patients, only patients with radiologically confirmed
benign (WHO grade I) meningioma of diameter B3.0 cm
were recruited. To ensure strict comparability between
treatment groups, microsurgery patients were excluded
when they could not have been treated with radiosurgery
instead (e.g., abutting optic structures or VIII nerve). In
addition, atypical (WHO grade II) and anaplastic or
malignant (WHO grade III) patients, patients with menin-
gioma diameter [3.0 cm, patients receiving fractionated
radiotherapy, and patients for whom follow-up cost data
was unavailable were excluded from this study. Recruit-
ment took place at the Department of Neurosurgery of the
Erasmus MC University Medical Center in Rotterdam
(microsurgery and LINAC radiosurgery) and at the
Department of Neurosurgery of the St. Elisabeth Hospital
in Tilburg (gamma knife radiosurgery). Enrolment took
place retrospectively in September 2008. All costs are
based on Euro 2007 cost data. Where necessary, costs were
adjusted to 2007 using the general price index from the
Dutch Central Bureau of Statistics [22].
The microcosting study
Initial treatment costs of microsurgery, LINAC radiosur-
gery, and gamma knife radiosurgery were based on a detailed
microcosting study, in which resource use and unit costs of
direct and indirect cost components were identified. Direct
cost components involved diagnostic procedures (medical
imaging and laboratory services), consumables (medications
and disposables), inpatient stay (at the normal ward and
intensive care unit), and labor (including neurosurgeons,
anesthesiologists, radiation oncologists, residents, physi-
cists, radiation technicians, operation assistants, and nurses).
In The Netherlands, the hospital rather than the government
owns its exploited equipment. In agreement with the
healthcare providers’ perspective, our study therefore addi-
tionally considered equipment. Indirect cost components
concerned overheads (general expenses, administration and
registration, energy, maintenance, insurance, and personnel
costs of nonpatient services such as management and
administration) and capital (depreciation of buildings and
inventory, and interest).
Resource use of diagnostic procedures, consumables,
inpatient stay, and equipment (number of treatments per
year) was available per individual patient, acquired from
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hospital information systems (bottom-up microcosting).
Resource use of labor was collected by means of stan-
dardized reporting templates; two medical specialists per
hospital department were asked to estimate resource use of
labor of an average meningioma patient matching the
inclusion criteria.
Unit costs of diagnostic procedures and medications
were taken from (financial) hospital databases. Annual
costs of disposables were obtained from hospital informa-
tion systems and divided by the annual number of inpatient
days to calculate unit costs per inpatient day. Resource use
of inpatient stay was valued using reference unit prices
[23]. Unit costs of labor were based on standardized costs
per minute, which equaled the normative income divided
by the number of workable minutes per year. Normative
incomes were based on collective labor agreements. Unit
costs of health care utilization are presented in Table 1.
Equipment was valued using replacement and mainte-
nance costs with a discount rate of 4% and anticipated life
expectancy of 10 years, as prescribed by the Dutch Health
Authority. The LINAC considered in our study was used
for fractionated (multiple fraction) as well as stereotactic
(single-fraction) treatments, whereas the gamma knife only
performed stereotactic treatments. To be able to determine
the influence of alternative calculation methods, equipment
costs were determined both per fraction and per treatment.
As patients receiving fractionated treatments were exclu-
ded from this study, the alternative calculation methods
were expected to have a substantial impact on the results.
Annual overhead and capital costs were taken from the
annual accounts 2006 and divided by direct costs. Thus,
indirect costs were allocated to patients using a marginal
mark-up percentage.
Follow-up costs
Follow-up costs included visits to healthcare providers
(including the general practitioner, medical specialist,
physiotherapist, social worker, and company physician),
medical imaging services, inpatient stay, medications, and
medical aids (such as wheelchairs, rolling walkers, and
walking canes). Follow-up costs involved all resource use
occurring during the first year after treatment, including
resource use which was unrelated to the meningioma
treatment.
Resource use of medical imaging services was based on
an established protocol, prescribing one magnetic reso-
nance imaging (MRI) at 13 weeks and one at 52 weeks
after initial treatment. Other resource use was obtained
from standardized questionnaires which were sent to the
home addresses of the recruited patients 4, 26 or 52 weeks
after initial treatment. The recall period was 4 weeks.
Annual follow-up resource use and costs were determined
by adding up the values per recall period. The values for
the time between the measurement periods (week 5–22 and
week 27–48) were established through linear interpolation.
However, resource use of medications was not linearly
interpolated when interpolation would lead to unrealistic
regimens. For example, patients may receive flucloxacillin
during the 4-week recall period. As flucloxacillin is gen-
erally given during a course of 5–10 days, its costs would
be included in the calculations but not linearly interpolated.
Resource use of visits to healthcare providers and
inpatient stay was valued using reference unit prices [23].
Unit costs of diagnostic procedures, medications, and
medical aids were taken from (financial) hospital dat-
abases. Because patients were asked whether they made
use of medical aids at every measurement time point, we
assumed a once-only purchase with life expectancy of
5 years. Unit costs of health care utilization are presented
in Table 2.Table 1 Unit costs of health care utilization, initial treatment
(€2007)
Medical imaging services
Computed tomography 207.50
Magnetic resonance imaging 269.90
Inpatient stay
Inpatient hospital day 386.28
Labor (per minute)
Medical specialist 1.46
Resident 0.56
Laboratory technician 0.56
Operation assistant 0.50
Nurse 0.43
Equipment (replacement costs)
Gamma knife 3,000,000.00
LINAC 2,500,000.00
Table 2 Unit costs of health care utilization, follow-up (€2007)
General practitioner (one visit) 21.35
Medical specialist (one visit) 59.20
Physiotherapist (one visit) 24.05
Social worker (one visit) 24.05
Company physician (one visit) 59.20
Magnetic resonance imaging 269.90
Inpatient hospital day 386.28
Walking cane 10.00
Rolling walkers 125.00
Wheelchair 200.00
DAISY playera 400.00
a Digital Accessible Information System player, audio book for
visually impaired patients
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Statistical analyses were conducted using the statistical
software program SPSS version 16.0 for Windows. In
addition to descriptive statistics, differences between
treatment groups and between follow-up scores were
assessed by means of one-way analysis of variance
(ANOVA) test for variables showing a normal distribution,
Kruskal–Wallis test for variables not normally distributed,
and Pearson chi-square test for variable fractions. To adjust
for multiple testing, ANOVA with post hoc (Bonferroni)
testing was additionally performed.
Results
A total of 143 benign meningioma patients were eligible
for this study at our two hospital sites between August
2007 and August 2008. These included 5 atypical (WHO
grade II) patients, 31 patients with meningioma diameter
[3.0 cm, 34 patients receiving fractionated radiotherapy,
and 14 patients whose follow-up cost data were unavail-
able. Thus, a total of 59 patients were recruited, of whom
18 underwent microsurgery, 15 underwent LINAC radio-
surgery, and 26 underwent gamma knife radiosurgery.
Specific attention was paid to selecting microsurgery
patients who could have been treated with radiosurgery
instead, thereby preventing important bias.
Table 3 presents the general characteristics at baseline of
the patients. LINAC radiosurgery patients reported lower
current health state (measured on visual analog scale, with 0
being worst imaginable health and 100 being best imaginable
health) compared with microsurgery and gamma knife
radiosurgery patients. Tumor volume of microsurgery
patients was significantly higher than that of LINAC and
gamma knife radiosurgery patients (ANOVA test: P \
0.001). No significant differences between treatment groups
were observed in any of the other general characteristics.
Table 3 General characteristics
of the patients at baseline
SD standard deviation
a Self-reported by the patients,
measured on visual analog scale
with score ranging from 0
(worst imaginable health) to 100
(best imaginable health)
b Not available
Microsurgery LINAC
radiosurgery
Gamma knife
radiosurgery
n 18 15 26
Age
\31 years 0% 7% 0%
31–50 years 44% 20% 35%
51–70 years 44% 67% 42%
[70 years 11% 7% 23%
Sex
Male 16.7% 26.7% 11.5%
Female 83.3% 73.3% 88.5%
Current health statea 75.0 (SD 5.8) 66.7 (SD 15.3) 80.0 (SD 11.1)
Location of meningioma
Parasagittal 11% 33% 0%
Convexity 11% 33% 15%
Tuberculum sellae 28% 0% 0%
Sphenoid ridge 22% 0% 0%
Olfactory groove 11% 13% 0%
Falcine, tentorial, and petroclival 17% 20% 42%
Cavernous sinus 0% 0% 15%
Cerebellopontine angle 0% 0% 27%
Tumor volume
\5 cm3 6% 60% 46%
6–10 cm3 6% 33% 42%
11–15 cm3 35% 7% 8%
16–20 cm3 24% 0% 0%
21–25 cm3 6% 0% 4%
26–30 cm3 18% 0% 0%
31–35 cm3 6% 0% 0%
Initial treatment duration (min) 348 (SD 115) 20 (SDb) 60 (SD 26)
Inpatient hospital days (days) 11.3 (SD 5.8) 1.0 (SDb) 1.0 (SDb)
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Hereinafter, values for the LINAC radiosurgery group
are presented using equipment costs per fraction, with
values using equipment costs per treatment in parenthesis.
The microcosting study
An overview of initial treatment costs per group, using
equipment costs per fraction, is given in Table 4. Initial
treatment costs were €12,288 for microsurgery, €1,547
(€2,198) for LINAC radiosurgery, and €2,412 for gamma
knife radiosurgery. There were no indications that the cost
variation within and between treatment groups was related
to any of the baseline characteristics. The higher costs for
microsurgery were predominantly due to inpatient stay
(€5,321) and indirect costs (€4,350).
The share of inpatient stay in total treatment costs was
43% in microsurgery, 25% (18%) in LINAC radiosurgery,
and 16% gamma knife radiosurgery. Microsurgery patients
were admitted for an average of 11.3 (SD 5.8) inpatient
days. For most patients, microsurgery was performed on
day 2 or 3 of admission. However, one patient underwent
surgery on day 4 and one patient on day 6 of admission.
Sixty-one percent of the microsurgery patients were
admitted to the intensive care unit for an average of
1.0 day. LINAC and gamma knife radiosurgery are out-
patient procedures. Therefore, costs for inpatient stay were
over ten times higher in microsurgery than in the other two
groups (€5,321 versus €386). Substantial cost variation was
found in inpatient stay costs obtained for individual
microsurgery patients (range €2,318–11,201).
The share of labor in total treatment costs was 15% for
microsurgery, 14% (10%) for LINAC radiosurgery, and
10% for gamma knife radiosurgery. Labor was also an order
of magnitude more expensive in microsurgery compared
with the other two groups (€1,901 compared with €211 and
€246). This was reflected by resource use of medical spe-
cialists, which amounted to 610 min in microsurgery
(neurosurgeons and anesthesiologists), 70 min in LINAC
radiosurgery, and 100 min in gamma knife radiosurgery
(neurosurgeons and radiation oncologists). Besides, the
microsurgical treatment required the involvement of resi-
dents (580 min), operation assistants (600 min), and nurses
(900 min), whereas the radiosurgical treatments only
required radiation technicians (180 min for LINAC radio-
surgery, 161 min for gamma knife radiosurgery) and
physicists (11 min for LINAC radiosurgery, 15 min for
gamma knife radiosurgery).
Accounting for 40% of total treatment costs, equipment
was a relatively important cost driver in gamma knife
radiosurgery. The replacement cost of the gamma knife
(€3,000,000) resulted in an annuity of €369,873. With
maintenance costs of €160,000 per year and an average of
550 fractions or treatments per year, equipment costs per
fraction or treatment were estimated to be €963. Similar
Table 4 Initial treatment costs
of microsurgery, LINAC
radiosurgery, and gamma knife
radiosurgery (using equipment
costs per fraction) (Euro 2007)
Microsurgery
(n = 18)
LINAC
radiosurgery
(n = 15)
Gamma knife
radiosurgery
(n = 26)
Diagnostic procedures
Medical imaging
services
289 351 280
Laboratory services 231 0 0
Consumables
Medications 134 1 5
Disposables 62 18 18
Inpatient stay
Normal ward 4,142 386 386
Intensive care unit 1,180 0 0
Labor
Medical specialist 888 102 146
Resident 328 0 0
Physicist 0 8 11
Radiation technician 0 101 90
Operation assistant 297 0 0
Nurse 388 0 0
Equipment 0 50 963
Overheads and capital 4,350 530 513
Initial treatment costs 12,288 1,547 2,412
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calculations for the LINAC resulted in equipment costs of
€50 per fraction and €701 per treatment.
The share of diagnostic procedures in initial treatment costs
ranged from 4% in microsurgery to 23% (16%) in LINAC
radiosurgery. However, absolute costs of medical imaging
services were comparable between treatment groups. At least
one MRI or computed tomography was performed for each
individual patient. Laboratory services were only carried out
in microsurgery patients (€231; SD €139).
Costs for consumables accounted for less than 2% of
initial treatment costs in all treatment groups. Phenytoin
and nadroparine were among the most costly medications
administered in microsurgery, and lidocaine and alfentanil
in gamma knife radiosurgery patients. Another costly
medication was dexamethasone, which was administered in
all groups on indication.
The proportion of overheads and capital in the initial
treatment costs was 35% for microsurgery, 34% (24%) for
LINAC radiosurgery, and 21% for gamma knife radiosurgery.
Follow-up costs
A questionnaire was completed by each of the recruited
patients. For the microsurgery group, 22% (4/28) of the
questionnaires were returned at 4 weeks, 44% (8/18) at
26 weeks, and 34% (6/18) at 52 weeks after treatment.
These percentages amounted to 20% (3/15), 40% (6/15),
and 40% (6/15) for the LINAC radiosurgery and 42%
(11/26), 31% (8/26), and 27% (7/26) for the gamma knife
radiosurgery group.
The fractions of patients visiting any medical specialist
were 61% for microsurgery, 20% for LINAC radiosurgery,
and 38% for gamma knife radiosurgery (Pearson chi-square
test: P = 0.054). For patients visiting the medical spe-
cialist, the annual number of visits amounted to 3, 6, and 4,
respectively (ANOVA test: P = 0.565).
The fractions of patients visiting the physiotherapist
were 28% for microsurgery, 40% for LINAC radiosurgery,
and 19% for gamma knife radiosurgery (Pearson chi-square
test: P = 0.366). Two LINAC radiosurgery patients, with
relatively low current health state at baseline, each received
eight physiotherapist visits during the 4-week recall period.
These visits were included in the calculations, but not
linearly interpolated. As a result, the annual number of
physiotherapist visits for patients visiting the physiothera-
pist amounted to nine for microsurgery, six (instead of ten)
for LINAC radiosurgery, and six for gamma knife radio-
surgery (ANOVA test: P = 0.848).
Statistical differences were found neither in the fractions
of patients visiting the general practitioner, social worker,
and company physician nor in the corresponding numbers
of visits per year. Resource use of medical imaging was
identical in the three groups according to the established
protocol. None of the patients were admitted for inpatient
stay. Medications were used by about 72% of the patients
in microsurgery and 73% and 65% in LINAC and gamma
knife radiosurgery, respectively. In each treatment group,
about one out of six patients made use of a medical aid. A
summary of follow-up costs (4 weeks per measurement
time point) is given in Table 5.
Table 5 Follow-up costs (4 weeks per measurement time point) (Euro 2007) (median)
Microsurgery LINAC radiosurgery Gamma knife radiosurgery
4 weeks 26 weeks 52 weeks 4 weeks 26 weeks 52 weeks 4 weeks 26 weeks 52 weeks
(n = 4) (n = 8) (n = 6) (n = 3) (n = 6) (n = 6) (n = 11) (n = 8) (n = 7)
General practitioner 5 (0) 19 (21) 25 (0) 7 (0) 11 (0) 0 (0) 6 (0) 21 (21) 3 (0)
Medical specialist 44 (59) 67 (59) 20 (0) 99 (59) 0 (0) 30 (0) 27 (0) 30 (30) 34 (0)
Physiotherapist 0 (0) 20 (0) 36 (36) 16 (0) 14 (12) 20 (0) 9 (0) 8 (0) 0 (0)
Social worker 0 (0) 0 (0) 4 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (0) 0 (0)
Company physician 15 (0) 15 (0) 10 (0) 39 (0) 10 (0) 0 (0) 22 (0) 7 (0) 0 (0)
Medical imaging services 0 (0) 49 (49) 42 (42) 0 (0) 49 (49) 42 (42) 0 (0) 49 (49) 42 (42)
Inpatient stay 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Medication 16 (13) 19 (5) 5 (3) 35 (52) 18 (13) 24 (15) 10 (4) 14 (4) 13 (1)
Medical aids 1 (0) 1 (0) 0 (0) 0 (0) 1 (0) 1 (0) 0 (0) 0 (0) 0 (0)
Total 82 (73) 189 (183) 141 (123) 197 (192) 212 (175) 134 (114) 74 (24) 161 (132) 92 (101)
SD 29 64 101 38 175 81 86 105 45
25 percentile 59 131 45 162 53 62 22 68 42
75 percentile 112 261 238 a 368 221 127 231 130
SD standard deviation
a Not available
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Annual follow-up costs for treatment-related and treat-
ment-unrelated resource use consumption were €2,041 for
microsurgery, €1,514 for LINAC radiosurgery, and €1,553
for gamma knife radiosurgery (Kruskal–Wallis test: P =
0.120).
Annual total costs, using equipment costs per fraction, are
presented in Table 6 and amounted to €14,329 for micro-
surgery, €3,060 (€3,711) for LINAC radiosurgery, and
€3,966 for gamma knife radiosurgery (Kruskal–Wallis test:
P \ 0.001). Annual total costs of LINAC and gamma knife
radiosurgery were not significantly different (P = 0.096).
Discussion
This study is the first to compare total costs of alternative
procedures in the treatment of meningioma patients. With
initial treatment cost of €12,288, microsurgery was the
most expensive treatment option. Most important cost
drivers were inpatient stay (43%), indirect costs (35%), and
labor (15%). This finding is in agreement with the study of
Wellis et al. [8], who found initial treatment costs of
microsurgery in patients harboring arteriovenous malfor-
mation, acoustic neuromas, meningiomas or brain metas-
tasis potentially amenable to radiosurgery (diameter
\0.3 cm) to be €12,979 in Germany (adjusted to 2007). In
their study, inpatient stay accounted for 33%, indirect costs
for 39%, and labor for 13% of initial treatment costs [8].
Banerjee et al. [6] determined initial treatment costs for
vestibular schwannoma patients in the USA to be €22,332.
However, they used general service charges rather than
actual costs, which may make comparison misleading [6].
The study of Cho et al. found treatment costs for cranial
base tumors (diameter \3.0 cm) to be €4,628 (adjusted to
2007) in Taiwan [12].
The two alternative methods for calculation of equip-
ment costs were found to substantially impact our results.
Initial treatment costs for gamma knife radiosurgery were
€866 more expensive using equipment costs per fraction
and €262 more expensive using equipment costs per
treatment compared with LINAC radiosurgery. Even
though the replacement values of the LINAC and gamma
knife are of the same magnitude (€2,500,000 versus
€3,000,000; Table 2), the average number of LINAC
fractions per year was about 9,200 compared with 550 for
the gamma knife. The results of our cost analysis suggest
that LINAC and gamma knife radiosurgery are equally
expensive when equipment is valued per treatment. This
finding confirms the results of Griffiths et al. [10], who
compared the equipment costs of the LINAC and gamma
knife in Australia. Griffiths et al. estimated gamma knife
radiosurgery to cost up to €1,057 more per fraction and to
€132 more per treatment over LINAC radiosurgery
(adjusted to 2007) [10].
Our results further imply that follow-up costs in the first
year after initial treatment affected the relative costs of the
alternative treatment options. Initial treatment costs for
microsurgery, LINAC radiosurgery, and gamma knife
radiosurgery correspond to the relative ratio 100:13(18):20.
However, this relative ratio decreased to 100:21(26):28
when follow-up costs were included (Table 6). The latter
finding is not in agreement with the results of Banerjee
et al. [6]. With follow-up costs in the first year after initial
treatment of approximately €5,200 for microsurgery
Table 6 Annual total costs of
microsurgery, LINAC
radiosurgery, and gamma knife
radiosurgery (using equipment
costs per fraction) (Euro 2007)
Microsurgery LINAC Gamma knife Kruskal–Wallis
Radiosurgery Radiosurgery Asymp. sig.
Initial treatment costs 12,288 1,547 2,412
Relative to microsurgery 100 13 20
Follow-up costs 2,041 1,514 1,553 0.120
General practitioner 270 66 143 0.212
Medical specialist 539 291 410 0.072
Physiotherapist 344 222 207 0.429
Social worker 26 0 17 0.675
Company physician 160 94 62 0.826
Medical imaging services 540 540 540 0.331
Inpatient stay 0 0 0 1.000
Medication 156 290 172 0.308
Medical aids 6 11 3 0.582
Relative to microsurgery 100 74 76
Total costs 14,329 3,060 3,966 0.000
Relative to microsurgery 100 21 28
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patients and €900 for gamma knife radiosurgery patients
(adjusted to 2007), they observed an increased relative ratio
when follow-up costs were added [6]. Because Banerjee
et al. [6] did not report resource use of individual cost
components, it is unclear which factors led to their dif-
ferent conclusion.
One limitation of our study was the inclusion of resource
use which was unrelated to meningioma treatment in the
follow-up costs. As LINAC radiosurgery patients reported
a lower current health state compared with patients in the
other two treatment groups, follow-up costs of LINAC
radiosurgery patients may have been relatively overesti-
mated compared with the situation in which only resource
use related to meningioma treatment would be considered.
For example, 73% of medication costs were not related or
possibly but not definitely related to meningioma treatment
for the LINAC radiosurgery group. These percentages
amounted to 67% in the microsurgery group and 68% in
the gamma knife radiosurgery group. Medications directly
related to meningioma treatment involved dexamethasone
(often in combination with proton pump inhibitor or his-
tamine H2-receptor antagonist) and anticonvulsants. Costs
for medical aids were exclusively related to meningioma
treatment for all three patient groups. Unfortunately it was
not possible to assess differences between resource use
related and unrelated to meningioma treatment for the other
cost components (visits to healthcare providers, medical
imaging services, and inpatient stay).
Our inclusion criteria restricted the recruitment of a
larger number of patients. To be able to make a truthful
comparison between microsurgery, LINAC radiosurgery,
and gamma knife radiosurgery patients, only patients with
radiologically confirmed benign (WHO grade I) meningi-
oma with diameter B3.0 cm were recruited. However, at
the Erasmus MC University Medical Center, microsurgery
and LINAC radiosurgery were not commonly performed in
meningioma with diameter B3.0 cm. Besides, the fact that
microsurgery patients were only included when they could
have been treated with radiosurgery instead limited
recruitment of microsurgery patients.
Consequently, our study included only a small sample of
patients, especially for the calculation of follow-up costs in
which the microcosting patient samples were further divi-
ded into three subgroups to be able to detect follow-up
costs at 4, 26, and 52 weeks. The small sample of patients
prevented us from further omitting patients due to differ-
ences in baseline characteristics. For example, the shares of
tuberculum sellae and sphenoid ridge patients were (not
significantly) higher and those of cavernous sinus and
cerebellopontine angle patients (not significantly) lower in
microsurgery. In addition, follow-up costs for the time
between measurement periods (week 5–22 and week
27–48) were established through linear interpolation,
which may have affected the results. Our results may
therefore not be representative of clinical treatment
patterns in The Netherlands. However, there were no
indications that the cost variation within and between
treatment groups was related to any of the baseline char-
acteristics. Moreover, costing studies which assess follow-
up costs are scarce, and thus we believe that our study
provides valuable insight into the relative costs of alter-
native procedures for treatment of meningioma.
To determine the uncertainty of the obtained cost esti-
mates, one-way sensitivity analyses were carried out by
individually varying each unit cost value between 50% and
150%. Although total costs changed 25–43% when the
initial treatment costs were varied, the relative ratio for
microsurgery, LINAC radiosurgery, and gamma knife
radiosurgery did not change substantially. The influence of
this variation appeared to be rather modest for the other cost
components. Total costs changed 1–2% when unit costs of
visits to the general practitioner were altered (follow-up
costs: 2–7%). This change amounted to 2–5% for visits to
the medical specialist (follow-up costs: 10–13%), 1–4% for
visits to the physiotherapist (follow-up costs: 7–8%), 2–9%
for medical imaging services (follow-up costs: 13–18%),
and 1–5% for medications (follow-up costs: 4–10%).
Meningioma may be treated with procedures other than
microsurgery, LINAC radiosurgery, and gamma knife
radiosurgery. Yano and Kuratsu suggested that conserva-
tive treatment with close monitoring may be the best
therapeutic strategy in asymptomatic meningioma patients
to avoid incidence of surgery-related morbidity [11]. Fur-
thermore, combination therapy of microsurgery and radi-
osurgery may be beneficial [7, 24]. When meningioma
does not respond favorably to microsurgery and/or radio-
surgery, alternative procedures may include chemotherapy,
immunotherapy, hormone therapy, gene therapy, and/or
toxins [5]. However, cost information on these treatment
options is not yet available.
Earlier studies by others suggested radiosurgery to be
more cost-effective than microsurgery [6, 12, 13]. Ruti-
gliano et al. concluded that radiosurgery resulted in
favorable costs per life year compared with surgical
resection in solitary metastatic brain tumors [19]. Myrseth
et al. observed significantly favorable posttreatment facial
nerve function, hearing, complication rates, and quality of
life for gamma knife radiosurgery over microsurgery in
unilateral vestibular schwannoma patients [13]. Unfortu-
nately, our study did not weigh the costs of meningioma
treatment against clinical outcome measures, which pre-
vented us from drawing conclusions regarding the relative
cost-effectiveness of the three investigated treatments. To
be able to better assist clinical decision-making for
meningioma patients, future studies should determine the
cost-effectiveness of microsurgery, LINAC radiosurgery,
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and gamma knife radiosurgery by including clinical out-
come measures and quality of life, preferably over a longer
timeframe.
Furthermore, future studies should consider productivity
costs due to absence from work and reduced efficiency at
paid and unpaid work. As our study was conducted from
the healthcare providers’ perspective, it disregarded pro-
ductivity costs. However, as radiosurgery is a minimally
invasive outpatient procedure, a productivity cost reduction
over microsurgery may be expected. Therefore, produc-
tivity costs could significantly affect the cost-effectiveness
of microsurgery, LINAC radiosurgery, and gamma knife
radiosurgery in meningioma patients [8, 12, 20].
Acknowledgements The authors would like to thank the employees
of the medical and financial departments of the Erasmus MC Uni-
versity Medical Center in Rotterdam and the St. Elisabeth Hospital in
Tilburg who provided resource use and cost data for the study. The
authors are grateful to Arnold Dijkstra, Peter Levendag, Susan
Moederscheim, Connie de Pan, and Saskia Schawo for their contri-
bution to this study. This study was supported by Elekta BV.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Riemenschneider MJ, Perry A, Reifenberger G (2006) Histolog-
ical classification and molecular genetics of meningiomas. Lancet
Neurol 5(12):1045–1054
2. Rockhill J, Mrugala M, Chamberlain MC (2007) Intracranial
meningiomas: an overview of diagnosis and treatment. Neurosurg
Focus 23(4):E1
3. Campbell BA, Jhamb A, Maguire JA, Toyota B, Ma R (2009)
Meningiomas in 2009: controversies and future challenges. Am J
Clin Oncol 32(1):73–85
4. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO
classification of tumours of the central nervous system. Acta
Neuropathol 114(2):97–109
5. D’Ambrosio AL, Bruce JN (2003) Treatment of meningioma: an
update. Curr Neurol Neurosci Rep 3(3):206–214
6. Banerjee R, Moriarty JP, Foote RL, Pollock BE (2008) Com-
parison of the surgical and follow-up costs associated with
microsurgical resection and stereotactic radiosurgery for vestib-
ular schwannoma. J Neurosurg 108(6):1220–1224
7. Bennett CL, Tigue CC, Fitzner KA (2007) The economics of
brain metastases. Cancer Treat Res 136:23–29
8. Wellis G, Nagel R, Vollmar C, Steiger HJ (2003) Direct costs of
microsurgical management of radiosurgically amenable intra-
cranial pathology in Germany: an analysis of meningiomas,
acoustic neuromas, metastases and arteriovenous malformations
of less than 3 cm in diameter. Acta Neurochir (Wien) 145(4):
249–255
9. Elia AE, Shih HA, Loeffler JS (2007) Stereotactic radiation
treatment for benign meningiomas. Neurosurg Focus 23(4):E5
10. Griffiths A, Marinovich L, Barton MB, Lord SJ (2007) Cost
analysis of Gamma Knife stereotactic radiosurgery. Int J Technol
Assess Health Care 23(4):488–494
11. Yano S, Kuratsu J (2006) Indications for surgery in patients with
asymptomatic meningiomas based on an extensive experience.
J Neurosurg 105(4):538–543
12. Cho DY, Tsao M, Lee WY, Chang CS (2006) Socioeconomic
costs of open surgery and gamma knife radiosurgery for benign
cranial base tumors. Neurosurgery 58(5):866–873 discussion
866–873
13. Myrseth E, Moller P, Pedersen PH, Vassbotn FS, Wentzel-Larsen
T, Lund-Johansen M (2005) Vestibular schwannomas: clinical
results and quality of life after microsurgery or gamma knife
radiosurgery. Neurosurgery 56(5):927–935 discussion 927–935
14. Perks JR, St George EJ, El Hamri K, Blackburn P, Plowman PN
(2003) Stereotactic radiosurgery XVI: isodosimetric comparison
of photon stereotactic radiosurgery techniques (gamma knife vs.
micromultileaf collimator linear accelerator) for acoustic neu-
roma—and potential clinical importance. Int J Radiat Oncol Biol
Phys 57(5):1450–1459
15. Mehta M, Noyes W, Craig B et al (1997) A cost-effectiveness and
cost-utility analysis of radiosurgery vs. resection for single-brain
metastases. Int J Radiat Oncol Biol Phys 39(2):445–454
16. Porter PJ, Shin AY, Detsky AS, Lefaive L, Wallace MC (1997)
Surgery versus stereotactic radiosurgery for small, operable
cerebral arteriovenous malformations: a clinical and cost com-
parison. Neurosurgery 41(4):757–764 discussion 764–766
17. Ott K (1996) A comparison of craniotomy and Gamma Knife
charges in a community-based Gamma Knife Center. Stereotact
Funct Neurosurg 66 Suppl 1:357–364
18. van Roijen L, Nijs HG, Avezaat CJ et al (1997) Costs and effects
of microsurgery versus radiosurgery in treating acoustic neuroma.
Acta Neurochir (Wien) 139(10):942–948
19. Rutigliano MJ, Lunsford LD, Kondziolka D, Strauss MJ, Khanna V,
Green M (1995) The cost effectiveness of stereotactic radiosurgery
versus surgical resection in the treatment of solitary metastatic brain
tumors. Neurosurgery 37(3):445–453 discussion 453-5
20. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stod-
dart GL (2005) Methods for the economic evaluation of health
care programmes. Oxford University Press, New York
21. Tan SS, Rutten FF, van Ineveld BM, Redekop WK, Hakkaart-van
Roijen L (2009) Comparing methodologies for the cost estima-
tion of hospital services. Eur J Health Econ 10(1):39–45
22. Centraal Bureau voor de Statistiek, Ministerie voor Volksgez-
ondheid Welzijn en Sport (2007) www.statline.nl
23. Oostenbrink JB, Koopmanschap MA, Rutten FF (2002) Stan-
dardisation of costs: the Dutch Manual for Costing in economic
evaluations. Pharmacoeconomics 20(7):443–454
24. Black PM, Villavicencio AT, Rhouddou C, Loeffler JS (2001)
Aggressive surgery and focal radiation in the management of
meningiomas of the skull base: preservation of function with
maintenance of local control. Acta Neurochir (Wien) 143(6):
555–562
J Neurooncol (2011) 101:237–245 245
123
